Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 12/20 | 0.52 |
| ▸ | GSK3B | P49841 | 12/20 | 0.52 |
| ▸ | HTR1F | P30939 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | WNT1 | P04628 | 2/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.45 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2268552 | 0.84 | DYRK1A (0.52) | DYRK1AGSK3BHTR1FPKMWNT1 | |
| SCHEMBL13363351 | 0.82 | ULK1 (0.46) | DYRK1AGSK3BDYRK1BMAPT | |
| SCHEMBL17339955 | 0.77 | PKM (0.60) | DYRK1AGSK3BPKMMKNK1KDM4E | |
| SCHEMBL1553445 | 0.76 | ROCK2 (0.62) | PKMKDM4EMAPT | |
| SCHEMBL22572992 | 0.74 | DYRK1A (0.55) | DYRK1AGSK3BPKMWNT1DYRK1B | |
| SCHEMBL26944401 | 0.72 | ALDH1A1 (0.54) | DYRK1AGSK3BPKMMKNK1KDM4E | |
| SCHEMBL20041320 | 0.72 | DYRK1A (0.53) | DYRK1AGSK3BWNT1DYRK1BMAPT | |
| SCHEMBL13592382 | 0.72 | MAPT (0.68) | PKMMKNK1MAPT | |
| SCHEMBL12813812 | 0.71 | DYRK1A (0.50) | DYRK1AGSK3BWNT1MKNK1ABL1 | |
| SCHEMBL4764375 | 0.71 | ROCK2 (0.52) | DYRK1AGSK3BWNT1MKNK1ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541572-B2 | Compounds for the treatment of inflammatory disorders | MERCK SHARP & DOHME CORP. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | MERCK SHARP & DOHME CORP. | 2012-01-12 | — | — | US | disclosed |
| WO-2010054279-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | SCHERING CORPORATION (US) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010181-A1 | COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY DISORDERS | TNF, ADAMTS1, ADAMTS7 | DYRK1A 4205/4885GSK3B 403/4885HTR1F 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.